Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
July 20, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
July 13, 2023 16:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
July 10, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
July 06, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
June 28, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
Atossa Therapeutics Announces $10M Stock Repurchase Program
June 27, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
June 22, 2023 16:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
June 21, 2023 10:13 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
June 14, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
June 12, 2023 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...